Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628524 | 0.94 | RORC (0.66) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628517 | 0.94 | RORC (0.70) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13637790 | 0.93 | RORC (0.63) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628471 | 0.93 | RORC (0.63) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628601 | 0.92 | RORC (0.58) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628565 | 0.90 | TRPV1 (0.64) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628529 | 0.89 | RORC (0.63) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628470 | 0.89 | RORC (0.65) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13637694 | 0.89 | TRPV1 (0.62) | RORCTRPV1EGLN2EGLN1EGLN3 | |
| SCHEMBL13628293 | 0.89 | TRPV1 (0.62) | RORCTRPV1EGLN2EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | RORC 514/4885TRPV1 3411/4885EGLN2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.